Monoclonal antibodies (mAbs) have rapidly become one the largest classes of new drugs approved for the treatment of cancer – 14 mAbs have been approved by the US FDA for cancer therapy. This book focuses on mAbs targeting EGFR and HER2 and, in five chapters, summarizes information on the use of these mAbs in colorectal cancer, breast cancer, lung cancer, genitourinary cancers, tumors of the skin, the CNS and the head and neck, and gynecologic malignancies.
